BCCCP Board Certified Critical Care Pharmacist Practice Test
The Board Certified Critical Care Pharmacist (BCCCP) credential is the premier certification validating specialized expertise in the pharmacotherapy of critically ill patients. Awarded by the Board of Pharmacy Specialties (BPS), this certification signifies that a pharmacist possesses the advanced knowledge and clinical skills required to manage complex medication regimens in high-acuity settings such as medical, surgical, cardiac, neurological, and trauma ICUs. Achieving BCCCP status demonstrates a mastery of evidence-based pharmacotherapy, pharmacokinetic/pharmacodynamic optimization, hemodynamic support, infectious disease management, and the management of life-threatening emergencies. It is recognized by healthcare institutions, regulatory bodies, and professional organizations as the gold standard for critical care pharmacy practice. Certification requires passing a rigorous examination and maintaining credentials through continuing professional development, ensuring certified practitioners remain at the forefront of this rapidly evolving specialty. The BCCCP credential elevates patient care standards, enhances multidisciplinary team collaboration, and solidifies the pharmacist's role as an essential provider in the critical care environment.
Preguntas de Muestra
Prueba algunas preguntas para ver cómo es el examen completo.
97 de 140 respuestas incluyen una referencia verificable.
In the ICU, a 60-year-old kidney transplant recipient on tacrolimus is being discussed on rounds for invasive aspergillosis. The bedside data show BP 82/46 mmHg after 30 mL/kg crystalloid, HR 124/min, lactate 5.1 mmol/L, creatinine rising from 0.9 to 1.8 mg/dL, and urine output 0.2 mL/kg/hr. Current therapies include tacrolimus, prednisone, meropenem, TMP-SMX prophylaxis, and continuous kidney replacement therapy with interruptions. The active problem requires voriconazole/isavuconazole, TDM, and interactions. The most recent albumin is low, but the value has been stable for three days. What should the critical care pharmacist recommend next?
In the ICU, a 69-year-old woman taking apixaban for atrial fibrillation is being discussed on rounds for precepting ICU learners. At a Thursday ICU operations meeting, a quality officer, a PGY2 critical care resident, a patient safety analyst, and the sepsis program manager review precepting ICU learners. The dashboard shows that the proposed policy must be ready before the next Joint Commission tracer visit. Email comments from two clinicians conflict with the medication-use data, and the implementation window is 14 days. The active problem requires entrustable tasks, feedback timing, and patient safety. A medication history includes an over-the-counter sleep aid used twice last week. What should the critical care pharmacist recommend next?
In the ICU, a 55-year-old man with alcohol-associated liver disease is being discussed on rounds for DOAC reversal monitoring. The bedside data show temperature 39.3 C, ANC 90 cells/uL, platelets 38,000/uL, bilirubin 2.4 mg/dL, and a tunneled catheter with mild tenderness. Current therapies include norepinephrine, intermittent fentanyl boluses, cefepime, stress-ulcer prophylaxis, and renal-dose adjusted enoxaparin. The active problem requires clinical hemostasis, renal clearance, timing, and lab limitations. The patient missed one outpatient follow-up appointment last month. Which interpretation should drive the medication plan?
In the ICU, a 60-year-old kidney transplant recipient on tacrolimus is being discussed on rounds for temporary transvenous pacing. The bedside data show FiO2 0.70, PEEP 12 cm H2O, plateau pressure 29 cm H2O, RASS -4 during proning, triglycerides 318 mg/dL, and QTc 512 ms. Current therapies include amiodarone, unfractionated heparin, vasopressin, insulin infusion, and a home medication list that includes diltiazem. The active problem requires recognizing medication contributors to bradycardia and pacing capture issues. A medication history includes an over-the-counter sleep aid used twice last week. Which pharmacist recommendation best fits the available data?
In the ICU, a 60-year-old kidney transplant recipient on tacrolimus is being discussed on rounds for quality improvement run chart. At a Thursday ICU operations meeting, the ICU medical director, a night-shift charge nurse, an antimicrobial stewardship pharmacist, and a resident physician review quality improvement run chart. The dashboard shows that two near misses occurred after midnight during a seven-day shortage period. Email comments from two clinicians conflict with the medication-use data, and the implementation window is 14 days. The active problem requires distinguishing common-cause from special-cause variation. The bedside monitor also shows occasional premature atrial contractions. Which pharmacist recommendation best fits the available data?